Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)

<Previous Article In Volume
Next Article In Volume>

Research Progress of Drug Therapy for Systemic Lupus Erythematosus

Authors
Huizhong Tan1, *
1College of Pharmacy, China Pharmaceutical University, Nanjing, China
*Corresponding author. Email: 2020192535@stu.cpu.edu.cn
Corresponding Author
Huizhong Tan
Available Online 29 December 2022.
DOI
10.2991/978-2-494069-31-2_64How to use a DOI?
Keywords
Systemic lupus erythematosus; Drug therapy; Non-drug treatment; Specific manifestations
Abstract

Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. The incidence varies worldwide, and the current global prevalence of SLE is approximately 10 cases per 2.41 million. [1] Among all these patients, women who are in their childbearing age make up most of the population. This kind of autoimmune inflammation disease decrease the quality of their life. Due to heterogeneity and the incomprehension of exact mechanism of SLE, though we have already developed different types of drug: Hydroxychloroquine, Glucocorticoids, Immunosuppressive (IS) drugs and Biological agents, and multi-drug combination is used in clinical treatment to improve long-term patient outcome, SLE is still very easy to relapse which increases organ damage and leads to poor disease prognosis. Drugs nowadays still treat the symptoms but not the root cause. SLE is a manifestation of the imbalance of various factors in the body. Correcting only the partial imbalance can only delay the damage to body. More precise disease assessment scale, updated detection technology, new therapeutic targets, and new biomarkers are in need.

Copyright
© 2022 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)
Series
Advances in Social Science, Education and Humanities Research
Publication Date
29 December 2022
ISBN
978-2-494069-31-2
ISSN
2352-5398
DOI
10.2991/978-2-494069-31-2_64How to use a DOI?
Copyright
© 2022 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Huizhong Tan
PY  - 2022
DA  - 2022/12/29
TI  - Research Progress of Drug Therapy for Systemic Lupus Erythematosus
BT  - Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022)
PB  - Atlantis Press
SP  - 521
EP  - 527
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-494069-31-2_64
DO  - 10.2991/978-2-494069-31-2_64
ID  - Tan2022
ER  -